Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

Robert W Motl, Jeffrey A Cohen, Ralph Benedict, Glenn Phillips, Nicholas LaRocca, Lynn D Hudson, Richard Rudick, Multiple Sclerosis Outcome Assessments Consortium, Robert W Motl, Jeffrey A Cohen, Ralph Benedict, Glenn Phillips, Nicholas LaRocca, Lynn D Hudson, Richard Rudick, Multiple Sclerosis Outcome Assessments Consortium

Abstract

The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with multiple sclerosis (MS). One of the MSOAC goals is acceptance and qualification by regulators of performance outcomes that are highly reliable and valid, practical, cost-effective, and meaningful in MS. This article addresses the history, application, and psychometric properties of one such MSOAC metric of ambulation or walking namely, the timed 25-foot walk (T25FW). The T25FW has strong reliability over both brief and long periods of time in MS across a large range of disability levels. The outcome of walking speed from the T25FW has obvious real-world relevance and has correlated strongly with other measures of walking and lower extremity function. The T25FW is responsive for capturing intervention effects in pharmacological and rehabilitation trials and has an established value for capturing clinically meaningful change in ambulation. Directions for future research involve validating clinically meaningful improvements on the T25FW as well as determining whether 20% change is clinically meaningful across the disability spectrum. Researchers might further consider synchronizing accelerometers and motion sensors with the T25FW for capturing walking speed in everyday life and the patient's real environment.

Keywords: Ambulation; gait; multiple sclerosis; reliability; validity; walking.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Diagram of the T25FW field. The person starts by standing behind the line on the left of the field. The person walks across the 25-foot field that is clearly marked with start and end points as quickly and safely as possible. The time in seconds is recorded when the person lifts one foot for starting the T25FW and ends upon breaking the plane of the end point with a foot. The test is performed twice, and time is averaged between trials in seconds.

References

    1. Murray TJ. Multiple sclerosis: The history of a disease. New York: Demos, 2005.
    1. Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord 2010; 3: 229–239.
    1. Hessen C, Bohm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: Gait and visual function are the most valuable. Mult Scler 2008; 14: 988–991.
    1. LaRocca NG. Impact of walking impairment in multiple sclerosis: Perspectives of patients and care partners. Patient 2011; 4: 189–201.
    1. Motl RW. Ambulation and multiple sclerosis. Phys Med Rehabil Clin N Am 2013; 24: 325–336.
    1. Kurtke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.
    1. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain 2000; 123: 1027–1040.
    1. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173–180.
    1. Schwid SR, Goodman AD, Mattson DH, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997; 49: 1419–1424.
    1. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical outcome measure. Brain 1999; 122: 871–882.
    1. Gronwall DMA. Paced auditory serial-addition task: A measure of recovery from concussion. Percept Mot Skills 1977; 44: 367–373.
    1. Mathiowetz V, Weber K, Kashman N, et al. Adult norms for Nine Hole Peg Test of finger dexterity. Occup Ther J Res 1985; 5: 24–38.
    1. Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008; 71: 1134–1141.
    1. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494–502.
    1. Pearson M, Bieberg G, Smart N. Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: A meta-analysis. Arch Phys Med Rehabil 2015; 96: 1339–1348.
    1. Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler 2012; 18: 914–924.
    1. Cohen JA, Reingold SC, Polman CH, et al. Disability outcome measures in multiple sclerosis clinical trials: Current status and future prospects. Lancet Neurol 2012; 11: 467–476.
    1. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome assessment. Mult Scler 1999; 5: 244–250.
    1. Nieuwenhuis MM, Van Tongeren H, Sorensen PS, et al. The six sport step test: A new measure for walking ability in multiple sclerosis. Mult Scler 2006; 12: 495–500.
    1. Rosti-Otajarvi E, Hamaiainen P, Koivisto K, et al. The reliability of the MSFC and its components. Acta Neurol Scand 2008; 117: 421–427.
    1. Learmonth YC, Paul L, Miller L, et al. Reliability and clinical significance of mobility and balance assessments in multiple sclerosis. Int J Rehabil Res 2012; 35: 69–74.
    1. Learmonth YC, Dlugonski D, Pilutti LA, et al. The reliability, precision, and clinically meaningful change of walking assessments in multiple sclerosis. Mult Scler 2013; 19: 1784–1791.
    1. Messick S. Validation of psychological assessment: Validation of inferences from persons’ responses and performances as scientific inquiry into score meaning. Am Psychol 1995; 50: 741–749.
    1. Pearson OR, Busse ME, van Deursen, et al. Quantification of walking mobility in neurological disorders. QJM 2004; 97: 463–475.
    1. Landy FJ. Stamp collecting versus science: Validation as hypothesis testing. Am Psychol 1986; 41: 1183–1192.
    1. Benedict RH, Drake AS, Irwin LN, et al. Benchmarks of meaningful impairment on the MSFC and BICAMS. Mult Scler 2016; 22: 1874–1882.
    1. Phan-Ba R, Pace A, Calay P, et al. Comparison of the timed 25-foot walk and the 100-meter walk as performance measures in multiple sclerosis. Neurorehabil Neural Repair 2011; 25: 672–679.
    1. Sandroff BM, Klaren RE, Motl RW. Relationships among physical inactivity, deconditioning, and walking impairment in persons with multiple sclerosis. J Neurol Phys Ther 2015; 39: 103–110.
    1. Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale score in persons with multiple sclerosis. BMC Neurol 2013; 13: 37.
    1. Sandroff BM, Motl RW, Sosnoff JJ, et al. Further validation of the Six-Spot Step Test as a measure of ambulation in multiple sclerosis. Gait Posture 2015; 41: 222–227.
    1. Goldman MD, Motl RW, Scagnelli J, et al. Clinically meaningful performance benchmarks in MS: Timed 25-foot walk and the real world. Neurology 2013; 81: 1856–1863.
    1. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 2008; 14: 383–390.
    1. Cavanaugh JT, Gappmaier VO, Dibble LE, et al. Ambulatory activity monitoring in individuals with multiple sclerosis. J Neurol Phys Ther 2011; 35: 26–33.
    1. Sosnoff JJ, Weikert M, Dlugonski D, et al. Quantifying gait impairment in multiple sclerosis using GAITRite technology. Gait Posture 2011; 34: 145–147.
    1. Motl RW, Learmonth YC, Wojcicki TR, et al. Preliminary validation of the short physical performance battery in older adults with multiple sclerosis. BMC Geriatr 2015; 15: 157.
    1. Motl RW, Dlugonski D, Suh Y, et al. Accelerometry and its association with objective measures of walking limitations in ambulatory adults with multiple sclerosis. Arch Phys Med Rehabil 2010; 91: 1942–1947.
    1. Motl RW, Pilutti LA, Sandroff BM, et al. Accelerometry as a measure of walking behavior in multiple sclerosis. Acta Neurol Scand 2013; 127: 384–390.
    1. Motl RW, Cadavid D, Sandroff BM, et al. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores. J Neurol Sci 2013; 335: 169–173.
    1. Benedict RH, Holtzer R, Motl RW, et al. Upper and lower extremity function and cognitive impairment in multiple sclerosis. J Int Neuropsychol Soc 2011; 17: 643–653.
    1. Pilutti LA, Dlugonski D, Pula JH, et al. Weight status in persons with multiple sclerosis: Implications for mobility outcomes. J Obes 2012; 2012: 868256.
    1. Bethoux FA, Palfy DM, Plow MA. Correlations of the timed 25-foot walk in a multiple sclerosis outpatient rehabilitation clinic. Int J Rehabil Res 2016; 39: 134–139.
    1. Filipovic Grcic P, Matijaca M, Lusic I, et al. Responsiveness of walking-based outcome measures after multiple sclerosis relapses following steroid pulses. Med Sci Monit 2011; 17: CR704–CR710.
    1. Baert I, Freeman J, Smedal T, et al. Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: A European multicenter study. Neurorehabil Neural Reapir 2014; 28: 621–631.
    1. Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: What is a reliable change? Neurology 2002; 58: 1294–1296.
    1. Kragt JJ, Van der Linden FA, Nielsen JM, et al. Clinical impact of 20% worsening on Timed 25-Foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult Scler 2006; 6: 286–290.
    1. Coleman CI, Sobieraj DM, Marinucci LN. Minimally important clinical difference of the Timed 25-Foot Walk Test: Results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin 2012; 28: 49–56.
    1. Hobart J, Blight AR, Goodman A, et al. Time 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology 2013; 80: 1509–1517.
    1. Jensen H, Ravnborg M, Mamoei S, et al. Changes in cognition, arm function and lower body function after slow-release Fampridine treatment. Mult Scler 2014; 20: 1872–1880.
    1. Cohen JA, Krishnan AV, Goodman AD, et al. The clinical meaning of walking speed as measured by the time 25-foot walk in patients with multiple sclerosis. JAMA Neurol 2014; 71: 1386–1393.
    1. Feys P, Gijbels D, Romberg A, et al. Effect of time of day on walking capacity and self-reported fatigue in persons with multiple sclerosis: A multi-center trial. Mult Scler 2012; 18: 351–357.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe